{"nctId":"NCT00128206","briefTitle":"Treatment of Latent TB Infection for Jailed Persons","startDateStruct":{"date":"2004-11"},"conditions":["Tuberculosis"],"count":364,"armGroups":[{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Isoniazid"]},{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rifampin"]}],"interventions":[{"name":"Isoniazid","otherNames":[]},{"name":"Rifampin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nThe inclusion criteria for this study will be San Francisco Jail inmates, age 18 or older (the jail does not house juveniles) having evidence of M. tuberculosis infection by positive tuberculin skin test (a documented reactive tuberculin skin test to 0.1 mL containing 5 Tuberculin Units) who meet current national criteria for therapy for tuberculosis infection and can provide informed consent.\n\nExclusion Criteria:\n\n* Ineligible for either therapy regimen for any of the following reasons:\n\n  1. history of treatment-limiting reaction to isoniazid or rifamycins;\n  2. pregnancy or breast feeding;\n  3. active tuberculosis;\n  4. an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3 times the upper limit of normal;\n  5. bilirubin \\>2 times the upper limit of normal;\n  6. platelets \\<150 K/mm3;\n  7. taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs);\n* Unable to communicate in English or Spanish;\n* Unable or unwilling to provide informed consent;\n* Not in the routine level of jail security for any reason (housed in \"special security\" areas);\n* Any condition that, in the best judgment of the investigator, would pose a risk to the subject during the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Laboratory Test or Clinical Judgment Resulting in the Need to Stop Study Medication","description":"Liver function tests were taken at regular intervals and clinical symptoms were reviewed at regular intervals in both study groups. On the basis of these tests and examinations, physicians determined whether the study drug needed to be stopped.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Completion of Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Cost Effectiveness","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":184},"commonTop":["skin rash","gastrointestinal symptoms","elevated liver function tests","injury"]}}}